Gilead Sciences (GILD) shares popped over 16% in after-hours trading on Thursday following encouraging anecdotal data from Gilead’s remdesivir COVID-19 trials.News source STAT reported on a video presentation within a single site, the University of Chicago, which recruited 125 COVID-19 patients into GILD’s phase III trials.According to the presentation, only 2 of the 113 severe patients died, fever curves for those presenting with fever reportedly fell after receiving remdesivir, and the investigator reportedly noted some ventilated patients coming off ventilators shortly after treatment.Moreover, investigators also reportedly noted that most patients were discharged within 6 days.RBC Capital’s Brian Abrahams admitted that …read more
Source:: Yahoo Finance
